Thursday, March 13, 2014
team at the Massachusetts Institute of Technology has figured out how
to ferry cancer vaccines into lymph nodes-a location that orchestrates immune
responses but has been hard to target directly. The key was tethering the
vaccines to albumin to hitchhike on the
carrier's normal transportation route.1
Amphiphiles, adjuvants and antigens
The team started by constructing a series of model
vaccines containing either peptide antigens or adjuvants conjugated to fatty
acid tails that would bind albumin.
Quaratino, senior medical director and immunology advisor at Merck KGaA, told SciBX that the rapid
accumulation in lymph nodes and powerful T cell immune response in the absence
of increased systemic toxicity was impressive.
B. SciBX 7(10); doi:10.1038/scibx.2014.277 Published online March 13, 2014
1. Liu, H. et
al. Nature; published online Feb. 16, 2014; doi:10.1038/nature12978
Contact: Darrell J. Irvine, Massachusetts Institute
of Technology, Cambridge, Mass.e-mail: email@example.com
2. Johansen, P. et al. J. Control. Release 148, 56-62 (2010)
3. Dranoff, G. Nat. Med. 19,
(LSE:AZN; NYSE:AZN), London, U.K.
Kite Pharma Inc.,
Los Angeles, Calif.
Massachusetts Institute of Technology, Cambridge, Mass.
(Xetra:MRK), Darmstadt, Germany
Swiss Federal Institute of Technology Lausanne, Lausanne, Switzerland